• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胆汁成分对瞬时通透性增强剂膜嵌入的影响。

Influence of Bile Composition on Membrane Incorporation of Transient Permeability Enhancers.

机构信息

Department of Pharmacy, Uppsala University, Husargatan 3, 751 23 Uppsala, Sweden.

The Swedish Drug Delivery Forum (SDDF), Uppsala University, Husargatan 3, 751 23 Uppsala, Sweden.

出版信息

Mol Pharm. 2020 Nov 2;17(11):4226-4240. doi: 10.1021/acs.molpharmaceut.0c00668. Epub 2020 Oct 8.

DOI:10.1021/acs.molpharmaceut.0c00668
PMID:32960068
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7610231/
Abstract

Transient permeability enhancers (PEs), such as caprylate, caprate, and salcaprozate sodium (SNAC), improve the bioavailability of poorly permeable macromolecular drugs. However, the effects are variable across individuals and classes of macromolecular drugs and biologics. Here, we examined the influence of bile compositions on the ability of membrane incorporation of three transient PEs-caprylate, caprate, and SNAC-using coarse-grained molecular dynamics (CG-MD). The availability of free PE monomers, which are important near the absorption site, to become incorporated into the membrane was higher in fasted-state fluids than that in fed-state fluids. The simulations also showed that transmembrane perturbation, ., insertion of PEs into the membrane, is a key mechanism by which caprylate and caprate increase permeability. In contrast, SNAC was mainly adsorbed onto the membrane surface, indicating a different mode of action. Membrane incorporation of caprylate and caprate was also influenced by bile composition, with more incorporation into fasted- than fed-state fluids. The simulations of transient PE interaction with membranes were further evaluated using two experimental techniques: the quartz crystal microbalance with dissipation technique and total internal reflection fluorescence microscopy. The experimental results were in good agreement with the computational simulations. Finally, the kinetics of membrane insertion was studied with CG-MD. Variation in micelle composition affected the insertion rates of caprate monomer insertion and expulsion from the micelle surface. In conclusion, this study suggests that the bile composition and the luminal composition of the intestinal fluid are important factors contributing to the interindividual variability in the absorption of macromolecular drugs administered with transient PEs.

摘要

瞬时渗透增强剂(PEs),如辛酸、癸酸和 SNAC(salcaprozate 钠),可提高生物通透性差的大分子药物的生物利用度。然而,其效果在个体和大分子药物和生物制剂之间存在差异。在这里,我们使用粗粒化分子动力学(CG-MD)研究了胆汁成分对三种瞬时 PEs(辛酸、癸酸和 SNAC)膜整合能力的影响。在空腹状态下,吸收部位附近的游离 PE 单体的可用性更高,更容易整合到膜中。模拟还表明,跨膜扰动,即 PEs 插入到膜中,是辛酸和癸酸增加通透性的关键机制。相比之下,SNAC 主要吸附在膜表面上,表明其作用模式不同。辛酸和癸酸的膜整合也受到胆汁成分的影响,在空腹状态下比在进食状态下更多地整合到膜中。使用两种实验技术:石英晶体微天平耗散技术和全内反射荧光显微镜,进一步评估了瞬时 PE 与膜相互作用的模拟。实验结果与计算模拟结果吻合良好。最后,使用 CG-MD 研究了膜插入的动力学。胶束组成的变化影响癸酸单体插入和从胶束表面排出的插入速率。总之,这项研究表明,胆汁组成和肠液腔的组成是影响瞬时 PE 给药的大分子药物吸收个体间变异性的重要因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e8a/7610231/c383cc9f7f01/mp0c00668_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e8a/7610231/fb9454d4144e/mp0c00668_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e8a/7610231/33523dcd358a/mp0c00668_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e8a/7610231/5238d3ba42a2/mp0c00668_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e8a/7610231/331b593560ef/mp0c00668_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e8a/7610231/99f6ab00ed68/mp0c00668_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e8a/7610231/31a32acae182/mp0c00668_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e8a/7610231/67be3186d287/mp0c00668_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e8a/7610231/a86be8e5845a/mp0c00668_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e8a/7610231/c383cc9f7f01/mp0c00668_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e8a/7610231/fb9454d4144e/mp0c00668_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e8a/7610231/33523dcd358a/mp0c00668_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e8a/7610231/5238d3ba42a2/mp0c00668_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e8a/7610231/331b593560ef/mp0c00668_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e8a/7610231/99f6ab00ed68/mp0c00668_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e8a/7610231/31a32acae182/mp0c00668_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e8a/7610231/67be3186d287/mp0c00668_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e8a/7610231/a86be8e5845a/mp0c00668_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e8a/7610231/c383cc9f7f01/mp0c00668_0010.jpg

相似文献

1
Influence of Bile Composition on Membrane Incorporation of Transient Permeability Enhancers.胆汁成分对瞬时通透性增强剂膜嵌入的影响。
Mol Pharm. 2020 Nov 2;17(11):4226-4240. doi: 10.1021/acs.molpharmaceut.0c00668. Epub 2020 Oct 8.
2
In Silico-Based Experiments on Mechanistic Interactions between Several Intestinal Permeation Enhancers with a Lipid Bilayer Model.基于计算机的几种肠道渗透增强剂与脂质双层模型的相互作用机制的实验研究。
Mol Pharm. 2022 Jan 3;19(1):124-137. doi: 10.1021/acs.molpharmaceut.1c00689. Epub 2021 Dec 16.
3
A head-to-head Caco-2 assay comparison of the mechanisms of action of the intestinal permeation enhancers: SNAC and sodium caprate (C).Caco-2 细胞模型中肠渗透促进剂:N-乙酰半胱氨酸和癸酸钠(C)作用机制的头对头比较。
Eur J Pharm Biopharm. 2020 Jul;152:95-107. doi: 10.1016/j.ejpb.2020.04.023. Epub 2020 May 6.
4
Characterization of the physicochemical interactions between exenatide and two intestinal permeation enhancers: Sodium caprate (C) and salcaprozate sodium (SNAC).研究外泌体与两种肠道渗透增强剂:癸酸钠(C)和萨氯普利钠(SNAC)之间理化相互作用的特性。
Int J Pharm. 2022 Oct 15;626:122131. doi: 10.1016/j.ijpharm.2022.122131. Epub 2022 Aug 24.
5
Gastrointestinal Permeation Enhancers Beyond Sodium Caprate and SNAC - What is Coming Next?超越癸酸钠和 SNAC 的胃肠道渗透增强剂 - 接下来会有什么?
Adv Sci (Weinh). 2024 Sep;11(33):e2400843. doi: 10.1002/advs.202400843. Epub 2024 Jun 17.
6
Enhancement of colonic drug absorption by the transcellular permeation route.通过跨细胞渗透途径增强结肠药物吸收。
Pharm Res. 1988 Dec;5(12):786-9. doi: 10.1023/a:1015992819290.
7
Impact of Sodium -[8-(2-Hydroxybenzoyl)amino]-caprylate on Intestinal Permeability for Notoginsenoside R1 and Salvianolic Acids in Caco-2 Cells Transport and Rat Pharmacokinetics.8-(2-羟基苯甲酰基)氨基辛酸钠对 Caco-2 细胞转运和大鼠药代动力学中人参皂苷 R1 和丹酚酸的肠通透性的影响。
Molecules. 2018 Nov 16;23(11):2990. doi: 10.3390/molecules23112990.
8
Absorption enhancement, mechanistic and toxicity studies of medium chain fatty acids, cyclodextrins and bile salts as peroral absorption enhancers.中链脂肪酸、环糊精和胆盐作为口服吸收促进剂的吸收增强、作用机制及毒性研究
Farmaco. 2005 Nov-Dec;60(11-12):884-93. doi: 10.1016/j.farmac.2005.08.008. Epub 2005 Oct 13.
9
Safety concerns over the use of intestinal permeation enhancers: A mini-review.肠道渗透促进剂使用的安全性问题:一篇综述短文
Tissue Barriers. 2016 Apr 12;4(2):e1176822. doi: 10.1080/21688370.2016.1176822. eCollection 2016 Apr-Jun.
10
Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C).用于大分子口服给药的肠道渗透促进剂:水杨醛丙酯磺酸钠(SNAC)与癸酸钠(C)的比较
Pharmaceutics. 2019 Feb 13;11(2):78. doi: 10.3390/pharmaceutics11020078.

引用本文的文献

1
Development of 3D-Printed Two-Compartment Capsular Devices for Pulsatile Release of Peptide and Permeation Enhancer.3D 打印双室囊泡装置用于脉冲式释放肽类药物和渗透增强剂
Pharm Res. 2024 Nov;41(11):2259-2270. doi: 10.1007/s11095-024-03785-0. Epub 2024 Nov 1.
2
Gastrointestinal Permeation Enhancers Beyond Sodium Caprate and SNAC - What is Coming Next?超越癸酸钠和 SNAC 的胃肠道渗透增强剂 - 接下来会有什么?
Adv Sci (Weinh). 2024 Sep;11(33):e2400843. doi: 10.1002/advs.202400843. Epub 2024 Jun 17.
3
Improved Therapeutic Efficacy of MT102, a New Anti-Inflammatory Agent, via a Self-Microemulsifying Drug Delivery System, in Ulcerative Colitis Mice.

本文引用的文献

1
Molecular Dynamics Simulations on Interindividual Variability of Intestinal Fluids: Impact on Drug Solubilization.分子动力学模拟肠道液个体间变异性:对药物增溶的影响。
Mol Pharm. 2020 Oct 5;17(10):3837-3844. doi: 10.1021/acs.molpharmaceut.0c00588. Epub 2020 Sep 4.
2
A head-to-head Caco-2 assay comparison of the mechanisms of action of the intestinal permeation enhancers: SNAC and sodium caprate (C).Caco-2 细胞模型中肠渗透促进剂:N-乙酰半胱氨酸和癸酸钠(C)作用机制的头对头比较。
Eur J Pharm Biopharm. 2020 Jul;152:95-107. doi: 10.1016/j.ejpb.2020.04.023. Epub 2020 May 6.
3
Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.
新型抗炎药MT102通过自微乳化药物递送系统在溃疡性结肠炎小鼠中提高治疗效果
Pharmaceutics. 2023 Dec 2;15(12):2720. doi: 10.3390/pharmaceutics15122720.
4
Gastrointestinal Permeation Enhancers for the Development of Oral Peptide Pharmaceuticals.用于口服肽类药物开发的胃肠道渗透促进剂
Pharmaceuticals (Basel). 2022 Dec 19;15(12):1585. doi: 10.3390/ph15121585.
5
SNAC for Enhanced Oral Bioavailability: An Updated Review.SNAC 增强口服生物利用度:最新综述。
Pharm Res. 2023 Mar;40(3):633-650. doi: 10.1007/s11095-022-03459-9. Epub 2022 Dec 20.
6
Micellar Composition Affects Lipid Accretion Kinetics in Molecular Dynamics Simulations: Support for Lipid Network Reproduction.胶束组成在分子动力学模拟中影响脂质积聚动力学:对脂质网络再现的支持。
Life (Basel). 2022 Jun 24;12(7):955. doi: 10.3390/life12070955.
7
Impact of Intestinal Concentration and Colloidal Structure on the Permeation-Enhancing Efficiency of Sodium Caprate in the Rat.肠道浓度和胶态结构对癸酸钠在大鼠体内渗透增强效率的影响。
Mol Pharm. 2022 Jan 3;19(1):200-212. doi: 10.1021/acs.molpharmaceut.1c00724. Epub 2021 Dec 20.
8
In Silico-Based Experiments on Mechanistic Interactions between Several Intestinal Permeation Enhancers with a Lipid Bilayer Model.基于计算机的几种肠道渗透增强剂与脂质双层模型的相互作用机制的实验研究。
Mol Pharm. 2022 Jan 3;19(1):124-137. doi: 10.1021/acs.molpharmaceut.1c00689. Epub 2021 Dec 16.
9
Mechanistic Understanding from Molecular Dynamics in Pharmaceutical Research 2: Lipid Membrane in Drug Design.药物研究中分子动力学的机理理解2:药物设计中的脂质膜
Pharmaceuticals (Basel). 2021 Oct 19;14(10):1062. doi: 10.3390/ph14101062.
10
Investigation of Self-Emulsifying Drug-Delivery System Interaction with a Biomimetic Membrane under Conditions Relevant to the Small Intestine.研究自乳化给药系统与仿生膜在与小肠相关条件下的相互作用。
Langmuir. 2021 Aug 24;37(33):10200-10213. doi: 10.1021/acs.langmuir.1c01689. Epub 2021 Aug 11.
口服司美格鲁肽对比度拉鲁肽在日本 2 型糖尿病患者中的安全性和有效性(PIONEER 10):一项开放标签、随机、阳性对照、3a 期临床试验。
Lancet Diabetes Endocrinol. 2020 May;8(5):392-406. doi: 10.1016/S2213-8587(20)30074-7.
4
Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.口服司美格鲁肽单药治疗日本 2 型糖尿病患者的剂量反应、疗效和安全性(PIONEER 9):一项 52 周、2/3a 期、随机、对照试验。
Lancet Diabetes Endocrinol. 2020 May;8(5):377-391. doi: 10.1016/S2213-8587(20)30075-9.
5
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.在伴有或不伴有二甲双胍的胰岛素治疗基础上加用口服司美格鲁肽与安慰剂治疗 2 型糖尿病患者的疗效、安全性和耐受性:PIONEER 8 试验。
Diabetes Care. 2019 Dec;42(12):2262-2271. doi: 10.2337/dc19-0898. Epub 2019 Sep 17.
6
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.口服司美格鲁肽对比恩格列净在二甲双胍控制不佳的 2 型糖尿病患者中的疗效:PIONEER 2 研究。
Diabetes Care. 2019 Dec;42(12):2272-2281. doi: 10.2337/dc19-0883. Epub 2019 Sep 17.
7
Simulation of diblock copolymer surfactants. II. Micelle kinetics.两亲嵌段共聚物表面活性剂的模拟。 II. 胶束动力学。
Phys Rev E. 2019 Jul;100(1-1):012603. doi: 10.1103/PhysRevE.100.012603.
8
Effects of absorption-modifying excipients on jejunal drug absorption in simulated fasted and fed luminal conditions.吸收改性赋形剂对模拟空腹和进食腔内条件下空肠药物吸收的影响。
Eur J Pharm Biopharm. 2019 Sep;142:387-395. doi: 10.1016/j.ejpb.2019.07.012. Epub 2019 Jul 12.
9
Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.口服司美格鲁肽灵活剂量调整与西格列汀治疗 2 型糖尿病的疗效和安全性(PIONEER 7):一项多中心、开放标签、随机、3a 期临床试验。
Lancet Diabetes Endocrinol. 2019 Jul;7(7):528-539. doi: 10.1016/S2213-8587(19)30194-9. Epub 2019 Jun 9.
10
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.口服司美格鲁肽在伴有中度肾功能损害的 2 型糖尿病患者中的疗效和安全性(PIONEER 5):一项安慰剂对照、随机、3a 期临床试验。
Lancet Diabetes Endocrinol. 2019 Jul;7(7):515-527. doi: 10.1016/S2213-8587(19)30192-5. Epub 2019 Jun 9.